Login Register Cart 0
Generic placeholder image

Letters in Organic Chemistry

Editor-in-Chief

ISSN (Print): 1570-1786
ISSN (Online): 1875-6255

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Synthesis of Spiro[cycloalkane-pyridazinones] with High Fsp3 Character Part 2*

Author(s): Csilla Sepsey Für, Eszter Judit Horváth, Áron Szigetvári, Miklós Dékány, László Hazai, György Keglevich and Hedvig Bölcskei*

Volume 18, Issue 5, 2021

Published on: 28 July, 2020

Page: [373 - 381] Pages: 9

DOI: 10.2174/1570178617999200728214211

Abstract

An extended compound library of spiro[cycloalkane-pyridazinones] with a high Fsp3 character is targeted. There are two possibilities to improve the physicochemical parameters of a drug candidate molecules or building blocks, either to replace the aromatic systems with bioisoster heteroaromatic moieties, e.g. with one or two nitrogen containing ring systems (pyridines, pyridazines, pyrimidines, etc.), or to increase the Fsp3 character of the compounds. Using a new synthetic approach, the Grignard reaction of 2-oxaspiro[4.5]decane-1,3-dione and 2-oxaspiro[4.4]nonane-1,3-dione with p-halophenyl- or p-alkylphenyl-magnesium bromide resulted in the formation of the corresponding 2-oxoethyl-cycloalkanecarboxylic acids, which served as starting materials for the pyridazinones by reaction with hydrazine or phenylhydrazine. The pyridazinones obtained were alkylated with methyliodide or benzylbromide. 16 Novel 4-tolyl- or 4-halophenyl-2,3-diazaspiro[5.5]undec-3-en-1-one and 4-tolyl- or 4-halopyhenyl-7,8-diazaspiro[4.5]dec-8-en-6-one, and their N-methyl, N-benzyl, and N-phenyl derivatives were synthetized. The physicochemical parameters and the Fsp3 character of the novel compounds obtained were studied. A few of them showed excellent logP and clogP values, but the introduction of a further phenyl group seemed to be disadvantageous.

Keywords: Grignard-reactions, fsp3 character, pyridazinone, spiro, 2-oxoethyl-cycloalkanecarboxylic acids, hydrazine.

« Previous Next »
Graphical Abstract

[1]
Sepsey Für, Cs.; Riszter, G.; Gerencsér, J.; Szigetvári, A.; Dékány, M.; Hazai, L.; Keglevich, Gy.; Bölcskei, H. Lett. Drug Des. Discov., 2020, 17(6), 731-744.
[2]
Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Ibid: Adv. Drug Delivery Rev., 2001, 46(1-3), 3-26.
[3]
Lipinski, C.A. Drug Discov. Today. Technol., 2004, 1(4), 337-341.
[http://dx.doi.org/10.1016/j.ddtec.2004.11.007] [PMID: 24981612]
[4]
Benet, L.Z.; Hosey, C.M.; Ursu, O.; Oprea, T.I. Adv. Drug Deliv. Rev., 2016, 101, 89-98.
[http://dx.doi.org/10.1016/j.addr.2016.05.007] [PMID: 27182629]
[5]
Veber, D.F.; Johnson, S.R.; Cheng, H.Y.; Smith, B.R.; Ward, K.W.; Kopple, K.D. J. Med. Chem., 2002, 45(12), 2615-2623.
[http://dx.doi.org/10.1021/jm020017n] [PMID: 12036371]
[6]
Gleeson, M.P. J. Med. Chem., 2008, 51(4), 817-834.
[http://dx.doi.org/10.1021/jm701122q] [PMID: 18232648]
[7]
Martin, Y.C. J. Med. Chem., 2005, 48(9), 3164-3170.
[http://dx.doi.org/10.1021/jm0492002] [PMID: 15857122]
[8]
Pajouhesh, H.; Lenz, G.R. NeuroRx, 2005, 2(4), 541-553.
[http://dx.doi.org/10.1602/neurorx.2.4.541] [PMID: 16489364]
[9]
Lovering, F.; Bikker, J.; Humblet, C. J. Med. Chem., 2009, 52(21), 6752-6756.
[http://dx.doi.org/10.1021/jm901241e] [PMID: 19827778]
[10]
Lovering, F. MedChemComm, 2013, 4, 515-519.
[http://dx.doi.org/10.1039/c2md20347b]
[11]
Ritchie, T.J.; Macdonald, S.J.F. Drug Discov. Today, 2009, 14(21-22), 1011-1020.
[http://dx.doi.org/10.1016/j.drudis.2009.07.014] [PMID: 19729075]
[12]
Ritchie, T.J.; Macdonald, S.J.F.; Young, R.J.; Pickett, S.D. Drug Discov. Today, 2011, 16(3-4), 164-171.
[http://dx.doi.org/10.1016/j.drudis.2010.11.014] [PMID: 21129497]
[13]
Aldeghi, M.; Malhotra, S.; Selwood, D.L.; Chan, A.W.E. Chem. Biol. Drug Des., 2014, 83(4), 450-461.
[http://dx.doi.org/10.1111/cbdd.12260] [PMID: 24472495]
[14]
Wermuth, C.G. MedChemComm, 2011, 2, 935-941.
[http://dx.doi.org/10.1039/C1MD00074H]
[15]
Singh, J.; Sharma, D.; Bansal, R. Future Med. Chem., 2017, 9(1), 95-127.
[http://dx.doi.org/10.4155/fmc-2016-0194] [PMID: 27957866]
[16]
Kauffman, R.F.; Robertson, D.W.; Franklin, R.B. Cardiovasc. Drug Rev., 1990, 8(4), 303-322.
[http://dx.doi.org/10.1111/j.1527-3466.1990.tb00398.x]
[17]
Sotelo, E.; Coelho, A.; Raviña, E. Chem. Pharm. Bull. (Tokyo), 2003, 51(4), 427-430.
[http://dx.doi.org/10.1248/cpb.51.427] [PMID: 12672999]
[18]
Combs, D.W.; Rampulla, M.S.; Bell, S.C.; Klaubert, D.H.; Tobia, A.J.; Falotico, R.; Haertlein, B.; Lakas-Weiss, C.; Moore, J.B. J. Med. Chem., 1990, 33(1), 380-386.
[http://dx.doi.org/10.1021/jm00163a061] [PMID: 2153210]
[19]
Moore, J.B. Biochem. Pharmacol., 1991, 42(3), 679-683.
[http://dx.doi.org/10.1016/0006-2952(91)90331-X] [PMID: 1650219]
[20]
Saini, M.; Mehta, D.K.; Das, R.; Saini, G. Mini Rev. Med. Chem., 2016, 16(12), 996-1012.
[http://dx.doi.org/10.2174/1389557516666160611015815] [PMID: 27290912]
[21]
Tao, M.; Aimone, L.D.; Gruner, J.A.; Mathiasen, J.R.; Huang, Z.; Lyons, J.; Raddatz, R.; Hudkins, R.L. Bioorg. Med. Chem. Lett., 2012, 22(2), 1073-1077.
[http://dx.doi.org/10.1016/j.bmcl.2011.11.118] [PMID: 22197136]
[22]
Li, D.B.; Rogers-Evans, M.; Carreira, E.M. Org. Lett., 2011, 13(22), 6134-6136.
[http://dx.doi.org/10.1021/ol2025313] [PMID: 22007769]
[23]
Burkhard, J.A.; Guérot, C.; Knust, H.; Carreira, E.M. Org. Lett., 2012, 14(1), 66-69.
[http://dx.doi.org/10.1021/ol2028459] [PMID: 22111917]
[24]
Li, D.B.; Rogers-Evans, M.; Carreira, E.M. Org. Lett., 2013, 15(18), 4766-4769.
[http://dx.doi.org/10.1021/ol402127b] [PMID: 23991674]
[25]
Carreira, E.M.; Fessard, T.C. Chem. Rev., 2014, 114(16), 8257-8322.
[http://dx.doi.org/10.1021/cr500127b] [PMID: 25003801]
[26]
Zheng, Y.; Tice, C.M.; Singh, S.B. Bioorg. Med. Chem. Lett., 2014, 24(16), 3673-3682.
[http://dx.doi.org/10.1016/j.bmcl.2014.06.081] [PMID: 25052427]
[27]
Pechnick, R.N.; Poland, R.E. J. Pharmacol. Exp. Ther., 2004, 309(2), 515-522.
[http://dx.doi.org/10.1124/jpet.103.060038] [PMID: 14742749]
[28]
Badger, A.M.; Schwartz, D.A.; Picker, D.H.; Dorman, J.W.; Bradley, F.C.; Cheeseman, E.N.; DiMartino, M.J.; Hanna, N.; Mirabelli, C.K. J. Med. Chem., 1990, 33(11), 2963-2970.
[http://dx.doi.org/10.1021/jm00173a010] [PMID: 2146392]
[29]
Norris, W.S.G.P.; Thorpe, J.F. J. Chem. Soc., 1921, 1199-1210.
[http://dx.doi.org/10.1039/CT9211901199]
[30]
Murata, Y.; Nishikata, T. Chemistry, 2018, 24(24), 6354-6357.
[http://dx.doi.org/10.1002/chem.201801065] [PMID: 29498461]
[31]
Stengel, T.; Maier, T.; Mann, A.; Stadlwieser, J.; Flockerzi, D. Novel Phthalazinone-Pyrrolopyrimidinecarboxamide Derivatives, WO 2012/171900 2012.
[32]
Van der Mey, M.; Hatzelmann, A.; Van Klink, G.P.M.; Van der Laan, I.J.; Sterk, G.J.; Thibaut, U.; Ulrich, W.R.; Timmerman, H. J. Med. Chem., 2001, 44(16), 2523-2535.
[http://dx.doi.org/10.1021/jm010838c] [PMID: 11472206]
[33]
Bölcskei, H.; Mák, M.; Dravecz, F.; Domány, Gy. ARKIVOC, 2008, 12, 182-193.

Rights & Permissions Print Cite
Article Metrics
17
1
© 2024 Bentham Science Publishers | Privacy Policy